Show simple item record

dc.contributor.authorPerez, Oliveren_US
dc.contributor.authorBracho, Gustavoen_US
dc.contributor.authorLastre, Miriamen_US
dc.contributor.authorMora, Nestoren_US
dc.contributor.authorCampo, Judith Delen_US
dc.contributor.authorGil, Danayen_US
dc.contributor.authorZayas, Caridaden_US
dc.contributor.authorAcevedo, Reinaldoen_US
dc.contributor.authorGonzalez, Domingoen_US
dc.contributor.authorLopez, Joseen_US
dc.contributor.authorTaboada, Carlosen_US
dc.contributor.authorSolis, Rosaen_US
dc.date.accessioned2017-05-03T16:58:39Z
dc.date.available2017-05-03T16:58:39Z
dc.date.issued2004en_US
dc.date.modified2009-12-21T06:45:39Z
dc.identifier.issn08189641en_US
dc.identifier.doi10.1111/j.1440-1711.2004.01293.xen_AU
dc.identifier.urihttp://hdl.handle.net/10072/27867
dc.description.abstractProteoliposomes (PL) from Neisseria meningitidis B have been widely used as a core antigen for antimeningococcal vaccination. PL contain major outer membrane proteins, LPS and phospholipids, and they induce a strong Th1 immune response, but they have low stability in solution. Attending to the need for new vaccine adjuvants, we developed a highly stable cochleate structure (CS) from PL using a technology that allows easy incorporation of new antigens. We explored the ability of PLCS to activate the immune system and its possible application as an adjuvant for parenteral and mucosal routes. Our results showed that PLCS were able to upregulate the expression of MHC class II and costimulatory molecules on human dendritic cells, as well as being able to stimulate the production of soluble mediators of a Th1 response, such as IL-12 and nitric oxide. High levels of anti-PL IgG were detected in serum after i.m. or mucosal (oral and nasal) administration, but also anti-PL secretory IgA was produced in saliva following nasal delivery. The immune response polarization to a Th1 pattern was confirmed by the induction of IgG2a antibodies, positive delayed type hypersensitivity reactions, and IFN-? production by splenocytes from immunized mice. The adjuvant potential was explored using PLCS containing ovalbumin (Ova). PLCS-Ova was able to elicit a substantial increase in anti-Ova IgG compared with Ova alone. In addition, a significant reduction in lesion size was observed in mice immunized with Leishmania major antigens in PLCS after challenge with virulent protozoa, suggesting at least partial modulation of the Th2 environment induced by this parasite. In conclusion, our results support the use of PLCS as a potent Th1 adjuvant for parenteral and mucosal vaccines.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_AU
dc.languageEnglishen_US
dc.language.isoen_AU
dc.publisherAustralasian Society for Immunologyen_US
dc.publisher.placeAustraliaen_US
dc.relation.ispartofpagefrom603en_US
dc.relation.ispartofpageto610en_US
dc.relation.ispartofissue6en_US
dc.relation.ispartofjournalImmunology and Cell Biologyen_US
dc.relation.ispartofvolume82en_US
dc.subject.fieldofresearchImmunology not elsewhere classifieden_US
dc.subject.fieldofresearchcode110799en_US
dc.titleNovel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular patternen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.date.issued2004
gro.hasfulltextNo Full Text


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record